Back to search
FDAFDA · Food and drugs·Recall number D-0742-2022

PAPAVERINE HYDROCHLORIDE Injection, USP, 60 mg/2mL (30 mg/mL), packaged as a) 25 x 2mL Single Use Vials per box (NDC 72516-024-25) and b) 10 x 2mL Single Use Vials per box (NDC 72516-024-10); Manufactured for Oryza Pharmaceuticals, Inc.

Published April 13, 2022 · Recall initiated: March 14, 2022

Summary

FDA records drug Class II recall D-0742-2022, published April 13, 2022 and initiated March 14, 2022. Recalling firm: Vitae Enim Vitae Scientific, Inc.; Status: Terminated; Reported quantity: a) 2,098 boxes; b) 700 boxes; Lot: Lot #: a) 20VPHI037, 20VPHI038, 20VPHI039, Exp 12/31/2022; 21VPHI021, 21VPHI022, 21VPHI023, Exp 6/30/2023; 21VPHI047, 21VPHI048, Exp 10/31/2023; b) 21VPHI023, Exp 6/30/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email if PAPAVERINE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
PAPAVERINE HYDROCHLORIDE
Manufacturer
Vitae Enim Vitae Scientific, Inc.
Distributor
Nationwide in the U.S.A
Lot
Lot #: a) 20VPHI037, 20VPHI038, 20VPHI039, Exp 12/31/2022; 21VPHI021, 21VPHI022, 21VPHI023, Exp 6/30/2023; 21VPHI047, 21VPHI048, Exp 10/31/2023; b) 21VPHI023, Exp 6/30/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was PAPAVERINE HYDROCHLORIDE Injection, USP, 60 mg/2mL (30 mg/mL), packaged as a) 25 x 2mL Single Use Vials per box (NDC 72516-024-25) and b) 10 x 2mL Single Use Vials per box (NDC 72516-024-10); Manufactured for Oryza Pharmaceuticals, Inc. recalled?

Yes. FDA published recall D-0742-2022 on April 13, 2022. Reported hazard: Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: PAPAVERINE HYDROCHLORIDE.